Sugi Predict

Sugi Predict / Compounds / SCHEMBL18791682

SCHEMBL18791682

SCHEMBL18791682

C[C@](O)(CC(=O)Nc1nc2ccc(C(F)(F)F)cc2n1-c1cc(F)cc(F)c1)C1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK1D P48730 2/20 0.40
▸ ROCK2 O75116 2/20 0.40
▸ EGFR P00533 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CCRL2 O00421 1/20 0.36
▸ S1PR1 P21453 3/20 0.35
▸ MCHR1 Q99705 2/20 0.35
▸ MAP3K7 O43318 2/20 0.35
▸ IRAK4 Q9NWZ3 2/20 0.35
▸ IRAK1 P51617 2/20 0.35
▸ ALK Q9UM73 2/20 0.35
▸ INSR P06213 1/20 0.35
▸ LCK P06239 1/20 0.35
▸ LTK P29376 1/20 0.35
▸ AXL P30530 1/20 0.35
▸ MAP4K2 Q12851 1/20 0.35
▸ MERTK Q12866 1/20 0.35
▸ BMI1 P35226 1/20 0.34
▸ RORC P51449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18791680 1.00 CSNK1D (0.40) CSNK1DROCK2EGFRUSP2SMN1; SMN2
SCHEMBL20111052 1.00 CSNK1D (0.40) CSNK1DROCK2EGFRUSP2SMN1; SMN2
SCHEMBL21771777 0.94 ALK (0.37) CSNK1DROCK2MCHR1IRAK1ALK
SCHEMBL18779215 0.90 EGFR (0.37) EGFRSMN1; SMN2MCHR1IRAK1ALK
SCHEMBL18779211 0.90 EGFR (0.37) EGFRSMN1; SMN2MCHR1IRAK1ALK
SCHEMBL17583013 0.89 CSNK1D (0.44) CSNK1DROCK2EGFRS1PR1MCHR1
SCHEMBL18791687 0.84 CSNK1D (0.43) CSNK1DROCK2EGFRUSP2SMN1; SMN2
SCHEMBL21375769 0.84 CSNK1D (0.43) CSNK1DROCK2EGFRUSP2SMN1; SMN2
SCHEMBL18779218 0.82 EGFR (0.36) CSNK1DROCK2EGFRMCHR1IRAK1
SCHEMBL18779172 0.81 CSNK1D (0.42) CSNK1DEGFRMCHR1IRAK1ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11724990-B2 Kv7 channel activators compositions and methods of use BIOHAVEN THERAPEUTICS LTD. (VG) 2023-08-15 — — US disclosed
US-20230000831-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE CHANNEL BIOSCIENCES, LLC 2023-01-05 — — US disclosed
US-20200062714-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2020-02-27 — — US disclosed
WO-2018081825-A1 BENZOIMIDAZOL-1, 2-YL AMIDES AS KV7 CHANNEL ACTIVATORS KNOPP BIOSCIENCES LLC (US) 2018-05-03 — — WO disclosed
US-20170114022-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS CHANNEL BIOSCIENCES, LLC 2017-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11724990-B2 Kv7 channel activators compositions and methods of use KCNA7, KCNK17, KCNAB1 CSNK1D 646/4885ROCK2 3519/4885EGFR 4338/4885
US-20230000831-A1 KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE KCNA7, KCNK17, KCNAB1 CSNK1D 646/4885ROCK2 3519/4885EGFR 4338/4885
US-20170114022-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNJ2, KCNK17 CSNK1D 290/4885ROCK2 3789/4885EGFR 4329/4885
US-20200062714-A1 BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS KCNA7, KCNJ2, KCNK17 CSNK1D 290/4885ROCK2 3789/4885EGFR 4329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.